Abstract : The overall efficacy and safety of anti-interleukin IL -13 therapies remain to be fully characterized. We conducted a meta-analysis of randomized controlled trials RCTs on the efficacy and safety of anti-IL-13 therapies compared with placebo in patients with uncontrolled asthma. This meta-analysis complied with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses PRISMA guidelines. The primary efficacy outcome was pulmonary function, and the primary safety outcome was the incidence rate of all adverse events AAEs . Secondary outcomes included asthma exacerbation, asthma control, and asthma-related quality of life QoL . Pooled estimates are presented as mean differences MDs , hazard ratios HRs or risk ratios RRs with 95 condence intervals CIs . Five RCTs of anti-IL-13 therapies, including tralokinumab, GSK679586, or lebrikizumab, met the criteria for study inclusion. The overall MD for change in forced expiratory volume in 1 second was 0.08 95 CI 0.02, 0.15 . 
Introduction
Increased global use of inhaled corticosteroids ICS has contributed to a signi cant reduction in the frequency of hospitalization for acute exacerbations in patients with bronchial asthma 1 2 . However, many patients do not achieve optimal asthma control despite a combination of ICS and other anti-asthma medications, including systemic glucocorticoids 3 . There is currently an unmet Review 1 
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medical need for further treatment options for these patients with uncontrolled asthma [1] [2] [3] .
Recently, humanized monoclonal antibodies mAb targeting inflammatory signaling and downstream pathways, such as anti-IgE mAb or anti-interleukin IL -5 mAb, have become available 4 5 .
These agents are now considered to be the cornerstone of therapeutic options in asthma treatment 2 6 .
Emerging and potential therapeutic targets include IL-13, which mediates many features of allergic in ammation associated with pulmonary diseases, such as goblet cell metaplasia, airway hyper-responsiveness, and mucus hypersecretion, which cause airway obstruction 4 7 .
Phase 3 studies have revealed that lebrikizumab, an IgG4 humanized mAb that binds IL-13 with high af nity, signi cantly improves pulmonary function and asthma-related quality of life QoL compared with placebo in uncontrolled asthma 8 . Moreover, in that study, the frequency of drug-related adverse events was similar between lebrikizumab and placebo 8 . Based on these results, lebrikizumab is now expected to be an effective and well-tolerated treatment option for patients with uncontrolled asthma. However, randomized controlled trials RCTs of anti-IL-13 therapies, such as lebrikizumab, tralokinumab an IL-13-speci c human mAb that binds to and neutralizes IL-13 , and GSK679586 a humanized mAb that inhibits IL-13 binding to both IL-13 receptor 1 and 2 , have reported mixed results regarding safety and efficacy outcomes ; this is due, in part, to differences in asthma severity or inclusion criteria among the studies [8] [9] [10] .
Therefore, the overall ef cacy and safety of anti-IL-13 therapeutic agents have not been fully evaluated and data remain limited.
A recent meta-analysis assessed the overall ef cacy and safety of anti-IL-13 therapeutic agents, including lebrikizumab and other agents, such as GSK679586 and tralokinumab 11 . That study highlighted the overall ef cacy and safety of anti-IL-13 therapies in asthma patients ; however, the severity of asthma varied among the RCTs included in that meta-analysis 11 . In our view, a meta-analysis of RCTs targeting patients with uncontrolled or moderate to severe asthma is essential to evaluate the ef cacy and safety pro les of anti-IL-13 therapies because these therapeutic options are required primarily for patients with refractory asthma. The aim of the present meta-analysis of RCTs was to compare the ef cacy and safety pro les of anti-IL-13 therapies with those of placebo in patients with uncontrolled asthma.
Methods

Literature search
A meta-analysis of RCTs was conducted to investigate the ef cacy and safety of anti-IL-13 therapies compared with placebo in patients with uncontrolled asthma. The meta-analysis complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA guidelines 12 13 . A literature search was conducted in MEDLINE PubMed , Scopus, and the Cochrane Library database up to July 2017 using the terms tralokinumab , lebrikizumab , GSK679586 , and asthma . PubMed was primarily used for the publication search because it is an open access database suitable for comprehensive literature searches. Scopus was used to ensure that all eligible articles were detected in PubMed. The Cochrane Library database was also searched for additional references. No restrictions were imposed on the search language. Additional relevant articles in the reference lists of the articles retrieved were also identi ed. The electronic databases were independently searched by two investigators KA and AT . In the case of discrepancies between the two investigators, a third investigator HS performed an additional evaluation, or the discrepancies were resolved by discussion with the research team.
Inclusion and exclusion criteria
Studies were considered eligible for inclusion in the present meta-analysis if they met the following criteria : 1 RCTs assessing the clinical ef cacy and safety of tralokinumab, lebrikizumab, or GSK679586 in adolescents or adults aged ≥ 12 years with a diagnosis of uncontrolled, severe, or moderate to severe asthma ; and 2 studies with outcomes including pulmonary function, any adverse event, asthma exacerbations, asthma control, or asthma-related QoL. Observational, casecontrol, cohort, and non-blinded clinical trials were excluded. All references were independently screened by KA and AT, in accordance with the inclusion and exclusion criteria.
Data extraction
Data from eligible studies were extracted on the basis of the prede ned criteria from articles included in the present meta-analysis. The prede ned primary ef cacy outcome was pulmonary function, assessed by changes in forced expiratory volume in 1 second FEV 1.0 . The prede ned primary safety outcome was the incidence rate of all adverse events. The prede ned secondary outcomes included asthma exacerbations, asthma control, and asthma-related QoL assessed by time to first exacerbation, change in Asthma Control Questionnaire-6 ACQ-6 score 14 , and change in Asthma Quality of Life Questionnaire AQLQ score 15 , respectively. If efficacy outcomes in studies were compared among patients divided into groups with high and low levels of biomarkers, only patients in the high biomarker groups were included in the present metaanalysis. If ef cacy outcomes were compared among patients treated with high and low doses of anti-IL-13 therapies, only patients in the high-dose groups were included in the present metaanalysis.
Risk of bias assessments
Cochrane-recommended methodology 16 was used to examine each study included in the present meta-analysis for the following : random sequence generation ; allocation concealment ; blinding of participants, personnel, or outcome assessment ; incomplete outcome data ; selective reporting ; and other forms of potential bias. The methodological quality of the included trials was also evaluated using the Jadad score, which grades studies based on their randomization, blinding, and dropout results 17 .
Statistical analysis
Statistical heterogeneity among the trials was assessed using the I 2 statistic 18 , which measures the degree of heterogeneity in outcome measures by calculating the percentage of the total variation among the studies included, with values of 50 or higher indicating signi cant heterogeneity. The signi cance of heterogeneity was tested using 2 statistics. Random effects models 19 were planned regardless of the presence of statistically signi cant heterogeneity.
Differences in the ef cacy and safety outcomes between the anti-IL-13 therapy and placebo groups were assessed, and pooled estimates are presented as the mean difference MD ; change in FEV 1.0 , change in ACQ-6, and chance in AQLQ , risk ratios RRs ; incidence of any adverse events , and hazard ratios HRs ; time to first asthma exacerbation with 95 confidence intervals CIs . Subgroup analysis by anti-IL-13 agent for primary ef cacy outcome change in FEV 1.0 was also performed. Publication bias was evaluated by a funnel plot and statistical analysis was performed using Egger s test 20 . All p-values are two-sided and p 0.05 was considered signi cant. All analyses were performed using RevMan version 5.3 ; Cochrane Corporation, Oxford, UK and STATA version 14.0 ; Stata Corp., College Station, TX, USA .
Results
Study selection, Jadad scores, and study characteristics
The study selection process is shown in Fig. 1 . In all, 109 articles were identi ed during the literature search : 52 were retrieved from PubMed, 46 were retrieved from Scopus, and 11 were retrieved from the Cochrane Library database. Of these, seven records remained after duplicates were removed. Based on screening of the title/abstract and full text, four reports with a total of 1,702 randomized patients intention to treat population were ultimately included in the present meta-analysis. Of these, one reported the results of two independent RCTs ; therefore, ve RCTs were nally included in this meta-analysis 8-10 21 . One study compared outcomes between a high biomarker group serum periostin ≥ 50 ng/ml or blood eosinophil count ≥ 300 cells/µl , a low biomarker group serum periostin 50 ng/ml and blood eosinophil count 300 cells/µl , and a placebo group 8 . According to the prede ned inclusion criteria for the present study, only the high biomarker group and placebo group were included in the meta-analysis. For all studies in the present meta-analysis, the exclusion criteria included a history of current or former smoking, treatment with maintenance oral corticosteroids, pregnancy, and recent parasitic infection. Two studies were assigned a Jadad score of 5 8 10 , one was assigned a score of 4 21 , and one was assigned a score of 3 9 , establishing the high quality of these studies. The study characteristics are listed in Table 1 .
Risk of bias
The risk of study bias was evaluated on the basis of random sequence generation selection bias ; allocation concealment selection bias ; blinding of participants performance bias , personnel, and outcome assessment detection bias ; incomplete outcome data attrition bias ; selective reporting reporting bias ; and other forms of potential bias. Each study was considered to have a low risk of bias for all factors, except for detection bias in two studies 9 21 and performance bias in one study 9 . The authors determinations of these assessments are shown in Fig. 2 .
Primary ef cacy outcome
Pulmonary function assessed by change in FEV 1.0 Pulmonary function was assessed by changes in FEV 1.0 in five RCTs 8-10 21 . In one study, ef cacy outcomes were compared between patients with high and low biomarker levels 8 ; in this case, only patients in the high biomarker group were included in the present meta-analysis. A further study assessed ef cacy outcomes of tralokinumab, comparing administration of the drug every 2 and 4 weeks 10 ; patients treated with tralokinumab every 2 weeks were included in the present meta-analysis. There was signi cant inter-study heterogeneity, measured by the I 2 statistic, and all analyses in the present study were performed using the random-effect model 
Primary safety outcome
All adverse events The incidence of all adverse events was assessed in three RCTs [8] [9] [10] . There was no signi cant inter-study heterogeneity, as measured using the I 2 statistic, and all analyses in the present study were performed using the random-effect model. There were no signi cant differences between anti-IL-13 therapies and placebo in terms of the incidence rate of all adverse events RR 1.03 ; 95 CI 0.86, 1.25 ; Fig. 4 .
Secondary outcomes
Asthma exacerbation Two RCTs assessed efficacy in terms of the prevention of asthma exacerbations, measured as time to the rst exacerbation 8 . The two studies compared outcomes between patients with high and low levels of biomarkers 8 , but only the high biomarker groups were included in the present meta-analysis. Furthermore, high and low doses of lebrikizumab were compared in those studies 8 , but only patients treated with high-dose tralokinumab were included in the present meta-analysis. There was no signi cant inter-study heterogeneity, as measured using the I 2 statistic, and all analyses in the present study were performed using the random-effect model. The results of the present meta-analysis of anti-IL-13 therapies revealed a signi cant reduction in asthma exacerbations, as assessed by time to rst exacerbation, compared with placebo HR 0.69 ; 95 CI 0.55, 0.87 ; Fig. 5 . Asthma control changes in ACQ-6 scores Asthma control was assessed by changes in ACQ-6 scores in three RCTs 9 10 21 . There was no signi cant inter-study heterogeneity, measured using the I 2 statistic, and all analyses in the present study were performed using the random-effect model. The results of the present meta- Fig. 4 . Forest plots of the risk ratio of all adverse events between patients treated with antiinterleukin IL -13 therapies and placebo. CI, confidence interval. analysis of anti-IL-13 therapies revealed a signi cant improvement in asthma control, as assessed by changes in ACQ-6 scores, compared with placebo MD 0.17 ; 95 CI 0.29, 0.04 ; Fig. 6 . Asthma-related QoL changes in AQLQ scores Asthma-related QoL was assessed by changes in AQLQ scores in three RCTs 9 10 21 . There was no signi cant inter-study heterogeneity, measured using the I 2 statistic, and all analyses in the present study were performed using the random-effect model. The results of the present meta-analysis of anti-IL-13 therapies revealed a signi cant improvement in asthma-related QoL, as assessed by changes in AQLQ scores, compared with placebo MD 0.19 ; 95 CI 0.08, 0.31 ; Fig. 7 .
Publication bias
Four studies evaluated differences in changes in FEV 1.0 between patients receiving anti-IL-13 therapies and those receiving placebo 8-10 21 , with Egger s funnel plot suggesting no publication bias p 0.816 ; Fig. 8 . Similarly, Egger s funnel plot indicated no publication bias for any of the other outcomes all p 0.05 ; data not shown ; therefore, the results of the meta-analysis are considered valid.
Discussion
In the present meta-analysis, the ef cacy of anti-IL-13 therapies in terms of pulmonary function and their safety from all adverse events were compared with placebo. The aim of this meta-analysis was to assess the overall ef cacy and safety of anti-IL-13 therapies.
The results of the analysis indicate that pulmonary function improved signi cantly following treatment with anti-IL-13 therapies compared with placebo. Subgroup analysis also demonstrated that the risk of deteriorating pulmonary function was signi cantly reduced and that pulmonary function improved significantly with tralokinumab and lebrikizumab, whereas there were no signi cant differences in pulmonary function between patients treated with GSK679586 and those receiving placebo. There was no signi cant difference in the incidence of all adverse events between the anti-IL-13-and placebo-treated groups.
Secondary outcome analyses revealed that, compared with patients receiving placebo, asthma exacerbations were signi cantly reduced and asthma control and asthma-related QoL improved signi cantly among patients treated with anti-IL-13 therapies.
Previous RCTs and meta-analyses of anti-IL-13 therapies have shown mixed results regarding ef cacy outcomes ; these apparent discrepancies are the result of differences among studies in asthma severity and definitions of complications, as well as differences in the dosage and frequency of administration 8-10 21 . Although only high biomarker or high-dose groups were included in the present meta-analysis, the results of the present study indicate the overall ef cacy of these therapies in terms of pulmonary function, prevention of asthma exacerbations, and asthma-related QoL. The difference in ACQ-6 scores detected in the present meta-analysis 0.17 was statistically, but not clinically, signi cant. This nding also indicates the ef cacy of anti-IL-13 therapies for asthma control. The ndings of the present study strongly support the use of anti-IL-13 therapies as an effective option for patients with uncontrolled asthma.
Regarding safety outcomes, the results of the present meta-analysis showed no signi cant differences in the incidence of all adverse events between the anti-IL-13 and placebo groups. This supports the overall safety of anti-IL-13 therapies. To the best of our knowledge, the present study is the rst meta-analysis to compare the efcacy and safety pro les of anti-IL-13 therapies and placebo in patients with uncontrolled asthma. We found that anti-IL-13 therapy was effective and generally well tolerated. In addition, the present analysis reports a novel nding, namely that pulmonary function, as assessed by FEV 1.0 , improved signi cantly in the tralokinumab-and lebrikizumab-treated groups compared with placebo, but not in patients treated with GSK679586.
The present study has several limitations that should be taken into consideration. First, only published studies were considered, and it is possible that publication bias may be present, although this was not apparent in the funnel plot. Second, a meta-analysis is a form of retrospective research that is subject to the same methodological limitations as retrospective studies. For example, all ve studies included in the present meta-analysis were supported by a pharmaceutical company, and the authors reported receiving grant support or uncompensated support. Therefore, the source of funding may have in uenced outcomes. Moreover, outcome selection bias may have occurred. Third, drug dosage and frequency of administration varied among the studies included in the present meta-analysis. Moreover, the total dosage of anti-IL-13 agents varied, due, in part, to different study durations, and this may have affected the nal conclusions. Finally, we only included a small sample of studies ve in our meta-analysis. Although metaanalyses involving a small sample of studies are not uncommon in orphan diseases, they may be confounded by the presence of heterogeneity.
In conclusion, we assessed the ef cacy and safety pro les of anti-IL-13 therapies compared with placebo. The results indicated that pulmonary function improved signi cantly in the anti-IL-13-treated group compared with placebo, and that there was no signi cant difference in the incidence of all adverse events between the two groups. These results suggest that anti-IL-13 therapies are effective and generally well tolerated in patients with uncontrolled asthma. Further studies are required to con rm the ef cacy and safety pro les of anti-IL-13 therapies in patients with uncontrolled asthma.
